Sentences with phrase «developments in immunotherapy»
«I am excited by recent developments in immunotherapy for cancer, and I think this is an area we can use to treat osteosarcoma.»
https://www.morrisanimalfoundation.org/ Not exact matches
With a critical mass of 450,000 patients annually among them, the six centers have agreed to combine their efforts on planning clinical trials in immunotherapy, recruit patients quickly, and share the information learned — which could be the single biggest factor in speeding up drug development.
«While we are disappointed CheckMate - 026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase III CheckMate - 227 study exploring the potential of the combination of Opdivo plus [our other cancer immunotherapy] Yervoy for PD - L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD - L1 negative patients,» he added.
Related Content Juno Halts Development of CAR T - Cell Cancer Immunotherapy Candidate JCAR015 Two More Deaths Reported in Juno Car - T Trial
The company's CAR T - cell cancer immunotherapy furthest in development at present is JCAR017.
Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies.
Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.
The research, which appears today as an advance online publication in the journal Nature, should aid development of more personalized cancer immunotherapy and advance diagnosis and treatment of infectious diseases.
In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.
The mouse model could also contribute to the further development of immunotherapies — a method in which the body's immune system is stimulated, so that it intensifies its fight against tumor cells.
Historically, the development of vitiligo in melanoma patients has been rare, but the recent use of immunotherapies, especially checkpoint inhibitors, has increased its incidence.
These lentivirus - induced DCs (iDCs) can be produced under good manufacturing practice - compliant conditions for immunotherapy against cancer and chronic viral infections, and are currently in clinical development.
Dr. Gnjatic's research focuses on human antigen - specific immune responses to tumor antigens, in an attempt to define new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.
«Our results support the further study and possible development of IL - 33 as adjuvants in vaccinations against pathogens, including in the context of antitumor immunotherapy,» says Weiner.
He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology and the 2017 Warren Alpert Foundation award for this work, which led to development of the PD - 1 pathway blockade for cancer immunotherapy.
Charles Akle, Chairman of Immodulon, said: «The results from this study are remarkable and represent a significant breakthrough in the development of immunotherapy for the treatment of pancreatic cancer.
The findings provide important insights into mechanisms used in cancer development and may have implications for cancer immunotherapy.
The researchers say the results warrant further development of neoantigen vaccines, both alone and in combination with other immunotherapy weapons such as checkpoint inhibitors.
With the development of new immunotherapies and targeted personalized medicine therapies, the glioblastoma treatment market is in rapid expansion and estimated to reach nearly $ 3.3 billion by 2024, with a fivefold increase in 10 years.
As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT 2018 invites international participants for high - level scientific exchange, collaboration, and education focused on cancer immunotherapy.
NEW YORK, August 29, 2016 — The Cancer Research Institute (CRI), a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced today that it will honor biotechnology company Amgen with the 2016 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research at its September gala in New York City.
An exciting area in drug development, immunotherapy is being increasingly utilized by patients with different cancer types.
The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.
My interest and expertise in immunotherapy started in early 1990s with animal models of IL - 2 and IL - 15 cytokines and natural killer cell development, continued with high dose IL - 2 studies and subsequently Phase I - III trials with both CTLA - 4 and PD1 / PDL -1 checkpoint inhibitors.
Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno - oncology (leveraging gut microbiota to impact tumor immunotherapy) 1 will be presented today by Sceneay et al in the late breaking poster session at the 2018 American Association for Cancer Research Annual Meeting (AACR) in Chicago.
«These are very promising findings and, as the first study to demonstrate protection from Zika in the pregnancy setting, are an important development in our efforts to combat Zika virus,» said Michael Diamond, M.D., Ph.D., Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology, and Associate Director, Center for Human Immunology and Immunotherapy Program at Washington University School of Medicine, and a lead author on the Cell paper.
We are leaders in the field of cancer immunotherapy and the development of tumor vaccines and new antibodies, working to activate the human body's own immune system to fight cancer.
Regardless of how immunotherapy could eventually influence cancer treatment, its development is a new revolution in cancer treatment, building on detailed biochemical knowledge of how cancer mutates and evades the immune response.
Through her Clinical Team Grant, Dr. Bhardwaj and Sacha Gnjatic, Ph.D., are investigating the relationship between checkpoint immunotherapy, chemotherapy, and mutations in advanced bladder cancer, to guide vaccine development and inform combination treatment approaches.
«Dr. Steinman's discovery of dendritic cells opens the door to advances in many areas, from vaccine development to cancer immunotherapy.
In the last decade the identification of genetic drivers of melanoma cell which regulate proliferation and survival - such as BRAF and other activators of the MAP - kinase pathway - along with the recent development of immunotherapy has taken away in many cases the invasive treatment of melanoma as an optioIn the last decade the identification of genetic drivers of melanoma cell which regulate proliferation and survival - such as BRAF and other activators of the MAP - kinase pathway - along with the recent development of immunotherapy has taken away in many cases the invasive treatment of melanoma as an optioin many cases the invasive treatment of melanoma as an option.
We are leaders in the development and advancement of immunotherapies, targeted therapies and personalised medicine.
In a previous post, we surveyed an exciting new development in rejuvenation biotechnology: the sudden emergence and rapid progress toward the clinic of vaccine - and antibody (Ab)- based immunotherapy to remove α - synuclein aggregates from the aging braiIn a previous post, we surveyed an exciting new development in rejuvenation biotechnology: the sudden emergence and rapid progress toward the clinic of vaccine - and antibody (Ab)- based immunotherapy to remove α - synuclein aggregates from the aging braiin rejuvenation biotechnology: the sudden emergence and rapid progress toward the clinic of vaccine - and antibody (Ab)- based immunotherapy to remove α - synuclein aggregates from the aging brain.
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
The Cancer Research Institute (CRI) and the Focused Ultrasound Foundation (FUSF) established a partnership in 2017 with the goal of advancing the development of new focused ultrasound (FUS) and cancer immunotherapy treatments.
Gosselies, Belgium — February 10, 2017 — iTeos Therapeutics SA, a Belgian privately - held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced that Michel Detheux, iTeos» Chief Executive Officer, will present at the 2017 BIO CEO & Investor Conference on Tuesday, February 14 2017 at 10:45 a.m. ET in Park North at The Waldorf Astoria in New York, NY.
Since that post, there have been exciting developments in the progress of the two most advanced of these immunotherapies: PD01A, the AS - targeting active vaccine from Austrian biotechnology startup AFFiRiS AG, developed using its patented «AFFITOME» neo-antigen discovery platform of molecular mimicry; and PRX002, a humanized monoclonal Ab (mAb) under development from Prothena Corp PLC, the successor of aggregate - clearing immunotherapy pioneer Élan Pharmaceuticals.
DENVER — Despite very encouraging progress in the development and use of immunotherapy for patients with non-small cell lung cancer, much confusion remains regarding patient selection for each therapy.
Gosselies, Belgium — July 28, 2017 — iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it has been granted EUR 7.5 million in non-dilutive funding * to support the clinical development of its lead anti-cancer drug.
Dr. Freeman's laboratory focuses on the identification and function of T cell costimulatory and coinhibitory pathways in regulating T cell activation and application of this knowledge to the development of more effective immunotherapies for cancer, infections, asthma, and autoimmune diseases.
Head and neck cancer has one currently approved immunotherapy, the checkpoint inhibitor nivolumab (Opdivo ®) and is one of the major cancer types for which new immune - based cancer treatments are in development.
His contributions to the development of PD - 1 immunotherapy for Hodgkin lymphoma received the Lymphoma Hub award for best research paper in lymphoma in 2014.
Research in the Leukemia Program spans from direction of clinical trials to basic molecular studies of leukemia biology, immunotherapy and development of novel agents, and to mitigating the late effects of treatment in long - term survivors.
The CIC contributes to the creation of white papers, response documents, and peer - reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.
Given the substantial increase in development activity and clinical success of other immunotherapy agents that followed, and in an effort to continue to provide maximum value to the rapidly evolving field, the direction of the CIC was re-set to become a «think tank» that would convene and tackle topics of importance to the continued development of cancer immunotherapies.
Several immunotherapies are currently approved by the FDA and many more are in clinical development.
The CIC was founded in 2002 as an international association of pharmaceutical and biotechnology companies and academic institutions with a common interest in immunotherapy research and development with the ultimate goal of making cancer immunotherapies part of the standard - of - care in oncology.
Stephen Alexander, UK - Cannabinoid receptors, transporters, endocannabinoid turnover, hydrogen sulphide turnover Arthur Christopoulos, Australia (GPCRs Liaison)- G protein - coupled receptors; analytical pharmacology; allosteric modulation; biased agonism; drug discovery; neuropharmacology John Cidlowski, USA (NHRs Liaison)- Glucocorticoid receptor signaling; apoptosis and the immune system Anthony P. Davenport, UK (Chair Evolving Pharmacology, GPCRs Liaison) Doriano Fabbro, Switzerland - Kinases and their biology, kinase inhibitors, drug discovery, pharmacology of drugs (kinase inhibitors) in the indication oncology, biology of oncology Kozo Kaibuchi, Japan Yoshikatsu Kanai, Japan - Transporters, amino acid signals, epithelial function, cancer biology Francesca Levi - Schaffer, Israel - eosinophils and mast cells as effector cells in allergic inflammation: characterization of new receptors / ligands, hypoxia / angiogenesis and eosinophils, asthma, atopic dermatitis, allergic rhinitis, immunopharmacological modulation of allergic diseases by bispecific recombinant antibodies, bacteria interactions with eosinophils and mast cells, the allergic effector unit, mast cell derived tumors: new antibody based treatment, the allergic inflammation and the resolvome, non IgE - mediated mast cell activation in diseases Eliot H. Ohlstein, USA (Editor)- Drug discovery and development, urogenital biology, cardiovascular / metabolic medicine John A. Peters, UK (LGICs Liaison) Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Joerg Striessnig, Austria (VGICs Liaison)- Physiology, pharmacology and pathophysiological role of voltage-gated calcium channels
At a minimum, however, the bioprocess community must prepare itself to meet the needs of both «pure» gene therapies and adoptive immunotherapies in development (Figures 2 and 3).